

14th September, 2009

To Whom It May Concern:

Yoshiji KIMURA
Representative Director of the Board and
Chief Executive Officer
MEDINET Co., Ltd.
(TSE-Mothers #2370)
2-5-14, Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa, Japan
Tel: +81 (0)45-478-0041 (Switch Board)
Email: ir@medinet-inc.co.jp

MEDINET Acquires Additional Shares in Lymphotec Inc.

[Translation for Information Purposes Only]

MEDINET Co., Ltd. ("MEDINET") announced that it acquired additional issued shares of Lymphotec Inc. ("Lymphotec") on 14th of September, 2009. As the consequence of such action, rate of its share holding become more than 10% of whole issued shares of Lymphotec.

1. Acquisition Details

Name and type of shares:	Common stock of Lymphotec Inc.
Number of acquired shares:	2,345 shares
	Shares held before acquisition: 645 shares
	Shares held after acquisition: 2,990 shares
Percentage of acquired shares:	10.2%
	Percentage held before acquisition: 2.2%
Date of acquisition:	14 th of September, 2009

2. Background on Acquisition of Additional Shares

Lymphotec is a biotech company which provides medical supporting service and sells reagents with related to Activated Lymphocyte Therapies to medical institutions.

Since Yasuda Enterprise Development Co., Ltd. (Chiyoda-ku, Tokyo) and MBL Venture Capital Co., Ltd. (Naka-ku, Nagoya) made a proposal of transferring Lymphotec shares, held by their managed venture funds, to MEDINET, MEDINET had careful considerations of benefit in its corporate strategic direction as well as evaluation with fair value of the acquisition price in a prudent manner. As a result of such consideration and evaluation, MEDINET agreed to accept their proposal for acquiring additional shares of Lymphotec offered by these companies.

3. Outline of Lymphotec

Representative: Teruaki SEKINE, Representative Director of the

	Board
Headquarters:	18-4 Fuyuki, Koto-ku, Tokyo, Japan
Foundation:	26 th of April, 1999
Business Pipelines:	1) Development of pharmaceutical drug with activated autologous lymphocyte therapies 2) Medical supporting service related with activated autologous lymphocyte therapies 3) Reagents for marketing, sales and distribution 4) Subcontract of basic and sponsored clinical research
Authorized Share Capital:	649,980 thousand yen (as of 31 st August, 2009)
Shares Outstanding:	29,308 shares
Major Shareholders:	Innocell Corporation 7,125 shares (24.3%) Teruaki Sekine 3,260 shares (11.1%) TS Holdings Ltd. 1,750 shares (6.0%)

4. Transferor of Lymphotoec Shares

1) Name: The Yasuda Enterprise Development I, Limited Partnership
Address: 4-2-7 Kojimachi, Chiyoda-ku, Tokyo, Japan
Number of sold shares: 1,545 shares
Prior relationship with the company: None

2) Name: Life Science Venture Fund
Address: 3-5-10 Marunouchi, Naka-ku, Nagoya-city, Aichi, Japan
Number of sold shares: 800 shares
Prior relationship with the company: None

5. Influence of Undertaking Acquisition of Lymphatic Shares on MEDINET's Financial Results.

The acquisition of these shares will have an immaterial effect on MEDINET's consolidated financial results for the year ending September 2009.